TY - JOUR
T1 - Long-term follow-up of chronic central serous chorioretinopathy after successful treatment with photodynamic therapy or micropulse laser
AU - van Rijssen, Thomas J.
AU - van Dijk, Elon H. C.
AU - Scholz, Paula
AU - Breukink, Myrte B.
AU - Dijkman, Greet
AU - Peters, Petrus J. H.
AU - Tsonaka, Roula
AU - Keunen, Jan E. E.
AU - MacLaren, Robert E.
AU - Hoyng, Carel B.
AU - Downes, Susan M.
AU - Fauser, Sascha
AU - Boon, Camiel J. F.
N1 - Funding Information: This study was supported by Stichting Macula Fonds; Retina Nederland Onderzoek Fonds; Stichting Blinden-Penning; Algemene Nederlandse Vereniging ter Voorkoming van Blindheid; Landelijke Stichting voor Blinden en Slechtzienden, which contributed through UitZicht (Delft, the Netherlands); Rotterdamse Stichting Blindenbelangen (Rotterdam, the Netherlands); Stichting Leids Oogheelkundig Ondersteuningsfonds (Leiden, the Netherlands); Haagse Stichting Blindenhulp (The Hague, the Netherlands); Stichting Ooglijders (Rotterdam, the Netherlands); Stichting Blindenhulp; Oxford NIHR Biomedical Research Centre (Oxford, United Kingdom); the Gisela Thier Fellowship of Leiden University, Leiden, the Netherlands (C.J.F.B.); and the Netherlands Organization for Scientific Research (VENI grant to C.J.F.B.). These funding organizations provided unrestricted grants and had no role in the design or conduct of this research. This investigator-initiated study received funding from Novartis Pharma B.V. (Arnhem, the Netherlands) solely for the purchase of verteporfin (Visudyne) to enable photodynamic therapy treatment at the Oxford site, because photodynamic therapy currently is not reimbursed routinely by the United Kingdom National Health Service for treating central serous chorioretinopathy. Novartis Pharma B.V. had no role in funding, designing, conducting or evaluating the study, nor in the writing of this manuscript. Publisher Copyright: © 2021 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd Copyright: Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/11
Y1 - 2021/11
N2 - Purpose: To describe the treatment outcomes and recurrence risk of chronic central serous chorioretinopathy (cCSC) in patients who had complete resolution of subretinal fluid (SRF) after either primary half-dose photodynamic therapy (PDT) or high-density subthreshold micropulse laser (HSML) in the PLACE trial. Methods: This multicentre prospective follow-up study evaluated cCSC patients at 1 year after completion of the PLACE trial. Outcomes included: complete resolution of SRF on OCT, best-corrected visual acuity (BCVA) in Early Treatment of Diabetic Retinopathy Study (ETDRS) letters, retinal sensitivity on microperimetry and a visual function questionnaire (NEI-VFQ25). Results: Twenty-nine out of 37 patients who received half-dose PDT and 15 out of 17 patients who received HSML could be evaluated at final visit. At final visit, 93% of the patients treated with half-dose PDT had complete resolution of SRF, compared with 53% of HSML-treated patients (p = 0.006). At final visit, the mean estimate increase in the PDT group compared with the HSML group was + 2.1 ETDRS letters, +0.15 dB for the retinal sensitivity and + 5.1 NEI-VFQ25 points (p = 0.103, p = 0.784 and p = 0.071, respectively). The mean estimated central retinal thickness in the half-dose PDT group was −7.0 µm compared with the HSML group (p = 0.566). The mean estimated subfoveal choroidal thickness in the half-dose PDT group was −16.6 µm compared with the HSML group (p = 0.359). Conclusion: At 20 months after treatment, cCSC patients successfully treated with half-dose PDT are less likely to have recurrences of SRF compared with those successfully treated with HSML. However, functional outcomes did not differ.
AB - Purpose: To describe the treatment outcomes and recurrence risk of chronic central serous chorioretinopathy (cCSC) in patients who had complete resolution of subretinal fluid (SRF) after either primary half-dose photodynamic therapy (PDT) or high-density subthreshold micropulse laser (HSML) in the PLACE trial. Methods: This multicentre prospective follow-up study evaluated cCSC patients at 1 year after completion of the PLACE trial. Outcomes included: complete resolution of SRF on OCT, best-corrected visual acuity (BCVA) in Early Treatment of Diabetic Retinopathy Study (ETDRS) letters, retinal sensitivity on microperimetry and a visual function questionnaire (NEI-VFQ25). Results: Twenty-nine out of 37 patients who received half-dose PDT and 15 out of 17 patients who received HSML could be evaluated at final visit. At final visit, 93% of the patients treated with half-dose PDT had complete resolution of SRF, compared with 53% of HSML-treated patients (p = 0.006). At final visit, the mean estimate increase in the PDT group compared with the HSML group was + 2.1 ETDRS letters, +0.15 dB for the retinal sensitivity and + 5.1 NEI-VFQ25 points (p = 0.103, p = 0.784 and p = 0.071, respectively). The mean estimated central retinal thickness in the half-dose PDT group was −7.0 µm compared with the HSML group (p = 0.566). The mean estimated subfoveal choroidal thickness in the half-dose PDT group was −16.6 µm compared with the HSML group (p = 0.359). Conclusion: At 20 months after treatment, cCSC patients successfully treated with half-dose PDT are less likely to have recurrences of SRF compared with those successfully treated with HSML. However, functional outcomes did not differ.
KW - central serous chorioretinopathy
KW - long-term follow-up
KW - micropulse laser
KW - photodynamic therapy
UR - http://www.scopus.com/inward/record.url?scp=85100721847&partnerID=8YFLogxK
U2 - https://doi.org/10.1111/aos.14775
DO - https://doi.org/10.1111/aos.14775
M3 - Article
C2 - 33565230
SN - 1755-375X
VL - 99
SP - 805
EP - 811
JO - Acta ophthalmologica
JF - Acta ophthalmologica
IS - 7
ER -